Rx Industry Post-M&A Integration, Part I
The long-term market cap of big pharma relies heavily on R&D pipeline valuation. But, in the wake of recent merger activity, most pharma companies have focused on producing short-term cost reductions in order to impress the financial markets. There is a way to reconcile these two, preserving the best of long-term R&D assets while cutting costs in other areas.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.